Shares of Globus Medical (GMED) are set to plummet 18.41% in pre-market trading on Friday, following the release of disappointing first-quarter 2025 financial results and a reduced earnings outlook. The medical device maker's performance fell short of analyst expectations, raising concerns about its growth trajectory.
Globus Medical reported adjusted earnings per share (EPS) of $0.68 for Q1, missing the analyst consensus estimate of $0.74 by 8.11%. This represents a 5.56% decrease compared to the same period last year. The company's quarterly sales also disappointed, coming in at $598.12 million, 4.44% below the analyst consensus estimate. Adding to investor concerns, Globus Medical cut its full-year 2025 adjusted EPS outlook to a range of $3.00 to $3.30, down from the previous guidance of $3.10 to $3.40.
In response to the earnings miss and lowered outlook, several analysts have cut their target prices for Globus Medical stock. Wells Fargo reduced its target from $93 to $76, Jefferies from $105 to $90, and RBC from $101 to $95. Despite the setback, Globus Medical reaffirmed its full-year 2025 revenue guidance in the range of $2.80 billion to $2.90 billion. CEO Dan Scavilla cited softer deal closures, temporary integration-related supply-chain disruptions, and the timing of international distributor orders as factors impacting the company's recent performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.